THALES
21.9.2022 10:09:38 CEST | Business Wire | Press release
With the past two years resulting in a permanently altered working environment, changes in security were both necessary and notable. Controlling access to applications, data, and systems is an increasingly important aspect of securing any environment and protecting it against both internal and external threats.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005005/en/
©Thales
After two years of the pandemic, confidence in addressing certain security risks and threats arising from hybrid and remote work has improved among businesses and organizations around the world. When it comes to secure access to applications, data, and systems, 84% IT professionals this year said they have some degree of confidence in their current user access security systems to enable remote work securely and easily, compared to 56% in 2021. In addition, 60% said this year they were highly confident compared to just 22% last year.
These are among some of the key findings from the 2022 Thales Access Management Index, a global survey of 2,600 IT decision makers, conducted by 451 Research, part of S&P Global Market Intelligence.
Firms Gaining Confidence Addressing Security of Remote Work
Overall, the report findings suggest that firms remain concerned about the security risks of remote work, but those concerns seem to be less severe. At the same time, firms are also growing more confident in the ability of authentication and access management systems to manage those risks. Only 31% of IT professional surveyed reported having “very high” concerns about the security risks and threats of remote work in 2022, down from 39% in 2021, while those who said they were “somewhat concerned” – the most popular response – increased from 43% to 48% in 2022.
Multi-Factor Authentication on the Rise But Not Widespread
While multi-factor authentication (MFA) usage remains most prevalent for remote workers (68%) and privileged users (52%), the report shows that MFA adoption is on the rise for internal and non-IT staff with MFA adoption increasing to 40% compared to 34% in 2021. However, widespread MFA adoption by businesses is still yet to be the norm with just over half (56%) have adopted MFA in their organizations.
Lingering Effects of Pandemic Drive Interest in Access Management, MFA and ZTNA
The survey inquired about direct impacts that the pandemic and remote work had on deployment plans for new access security technologies. Responses revealed a six-percentage-point global increase in plans to deploy stand-alone MFA, up from 31% in 2021. The pandemic also impacted plans to deploy cloud-based access management, selected by 45% of respondents worldwide compared to 41% in 2021. These two increases illustrate respondents’ growing awareness that threats come from all angles, and that proper authentication and management of access and privileges is necessary for an adequate security foundation. Last year, Zero Trust Network Access/Software-Defined Perimeter (ZTNA)/(SDP) was the top choice, selected by 44% of respondents. In 2022, ZTNA was the second choice at 42%.
Francois Lasnier, Vice President of Access Management Solutions at Thales comments: “The past few years have cemented remote work and work-from-anywhere as a permanent part of the security landscape, and they have also introduced new security risks and challenges. However, growing familiarity with remote work has ultimately broadened awareness on an enterprise level of daily business security risks and has strengthened both confidence and ability in security teams and products to handle those risks and threats properly.”
Garrett Bekker, Principal Analyst at 451 Research comments: “Just as the threat landscape has evolved, the tools and methods to handle the landscape have, too. However, even with innovative tools and boosted confidence levels, security plans and approaches still need to adapt to the ever-changing threat environment. A greater shift towards a Zero Trust model would place access management in a central role in corporate security strategies, with a related reliance on MFA as a critical supporting enabler.”
Thales and 451 Research will discuss the findings in more detail during a webinar on 29 September 2022. To join, please visit the registration page.
About the 2022 Thales Access Management Index
As organizations step beyond the urgent actions of the last two years, they’re grappling with securing the more complex environments in which they now operate. The global edition of the 2022 Thales Access Management Index looked at various aspects of those impacts in a wide-ranging survey of security professionals and executive leadership that touched on issues including access management and access security, multi-factor authentication, zero-trust network access, security spending plans, remote work and VPNs, and ransomware. The 2022 Thales Access Management Study is based on data from a survey of nearly 2,800 security professionals and executive leaders in more than 15 countries across the globe. This research was conducted as an observational study and makes no causal claims.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.
PLEASE VISIT
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005005/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
